Ally Bridge Group NY LLC boosted its position in Context Therapeutics Inc. (NASDAQ:CNTX – Free Report) by 159.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,886,232 shares of the company’s stock after purchasing an additional 1,160,281 shares during the quarter. Context Therapeutics comprises 2.3% of Ally Bridge Group NY LLC’s holdings, making the stock its 23rd biggest position. Ally Bridge Group NY LLC owned approximately 2.52% of Context Therapeutics worth $3,782,000 at the end of the most recent quarter.
Separately, Opaleye Management Inc. acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $1,102,000. 14.03% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 16th.
Context Therapeutics Price Performance
Shares of NASDAQ:CNTX opened at $2.26 on Monday. The stock’s 50 day moving average price is $2.31 and its 200 day moving average price is $1.88. The stock has a market cap of $169.50 million, a price-to-earnings ratio of -1.70 and a beta of 2.31. Context Therapeutics Inc. has a 12 month low of $0.77 and a 12 month high of $2.75.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. On average, sell-side analysts expect that Context Therapeutics Inc. will post -0.31 EPS for the current year.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Darden Restaurants Is on the Verge of a Significant Breakout
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Onsemi Could Be Set Up For a Solid Rebound: Here’s Why
- How to Calculate Options Profits
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
Want to see what other hedge funds are holding CNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Context Therapeutics Inc. (NASDAQ:CNTX – Free Report).
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
